HEALTH CARE
From Times Staff and Wire Reports
FDA to Review Growth Drug: A Food and Drug Administration advisory panel will decide today whether to recommend Genentech Inc.’s Nutropin drug for use in treating growth failure in children with chronic kidney problems--about 2,000 American children. But South San Francisco-based Genentech hopes to get FDA approval for the drug for other uses as well. The largest potential market for Nutropin is in treatment of children who can’t naturally produce enough growth hormones. Genentech expects to put Nutropin on the market for growth hormone inadequacy by March.
